AllaChem Announces the Beginning of Phase I Clinical Studies of AV4025, a Potent Small Molecule for the Treatment of Chronic Hepatitis C Infection

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

August 5, 2013 -- AllaChem, LLC announces the beginning of Phase I clinical studies of AV4025, a potent small molecule for the treatment of chronic hepatitis C infection. Hallandale Beach, Fl – July 25, 2013 - Alla Chem, LLC announced today the initiation of phase I clinical studies with AV4025, a next in-class small molecule HCV NS5A Inhibitor for the treatment of chronic hepatitis C infection. A double-blind, placebo-controlled, single ascending dose (10, 20 and 40 mg) study will evaluate safety, tolerability and pharmacokinetics of AV4025 upon oral administration in 30 healthy volunteers. The results of the pre-clinical and clinical studies will be presented at the 10th International Conference "Viral Hepatitis: Epidemiology, Diagnostics, Treatment and Prevention", September 17-19, 2013, Moscow, Russian Federation.


Alena Ivachtchenko, MBA

Director Business Development

Phone: 1-858-35-6627


Help employers find you! Check out all the jobs and post your resume.

Back to news